Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

TSXV:BTI.H - Post Discussion

biOasis Technologies Ord Shs > And I agree with craighenry about xb3...it does not work
View:
Post by zwerp2000 on Jun 21, 2023 2:27pm

And I agree with craighenry about xb3...it does not work

If it did, someone would have come forward to use it. Cheisi looked at it and then dropped it. Prothena worked with it and then gave up. No one else saw any value to it to scoop this company up for at least a few cents. The writing is and has been on the wall. How JD/prophet sees this any other way indicates why they had everything wrong on this one
Comment by Boomskid on Jun 21, 2023 2:59pm
We understand, zwerp, that you cannot understand that the payloads may also fail. Bioasis has never taken the risk of proving xB3 in a preclinical study. Why would any pharma make a deal with Bioasis when Bioasis has failed for 15 years to back xB3 by testing it inhouse? And then, we've had 3 CEOs in 6 years. That means trouble at the mangement/BoD level. How can any company be confident in ...more  
Comment by zwerp2000 on Jun 21, 2023 3:16pm
LOL, yeah, sure....sure. Whatever you say
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities